Steve is a life sciences executive with over 25 years of experience advising and financing healthcare companies across every stage of growth. Throughout his career, he has raised more than $3.4 billion through venture capital, IPOs and follow-on financings, while advising on over $17 billion in strategic transactions, including mergers, acquisitions and licensing deals.

He has worked extensively with biotechnology companies, investors and global pharmaceutical partners, helping transform innovative science into investable businesses.

At DNAmic, Steve leads the fundraising, partnering and corporate strategy for the Duchenne Muscular Dystrophy program, supporting its growth from early development through strategic collaborations and commercialization.